A breast-cancer triplet kept the disease away more than twice as long — and far fewer women had to quit it

For women whose advanced breast cancer carries a PIK3CA mutation, a new three-drug combination bought real time. In the Phase 3 VIKTORIA-1 study, presented at the ESMO congress on Saturday, the gedatolisib triplet held cancer back for a median of 21.5 months in women without liver spread, versus 9.1 months on the standard pairing — and 59% saw their tumours respond. Just as striking, only about 5% stopped the new treatment because of side effects, compared with 19% on the standard.

SDG 3 · Good health and well-being — Mechanism: tech innovation